News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

InterMune, Inc. (ITMN) Reports Second Quarter 2013 Financial Results and Business Highlights


7/25/2013 6:36:46 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

InterMune reported EsbrietĀ® (pirfenidone) revenue in the second quarter of 2013 of $14.4 million, compared with $5.5 million of Esbriet revenue in the same quarter of 2012. Sequentially, Esbriet revenue in the second quarter of 2013 increased 37 percent from $10.5 million in the first quarter of 2013.

Help employers find you! Check out all the jobs and post your resume.

Read at PR Newswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES